🚀 VC round data is live in beta, check it out!
Daxor Valuation Multiples
Discover revenue and EBITDA valuation multiples for Daxor and similar public comparables like Accuray, Optomed, Pangaea Oncology, InspireMD and more.
Daxor Overview
About Daxor
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Founded
1971
HQ
Employees
12
Website
Financials (LTM)
EV
$67M
Daxor Financials
Daxor reported last 12-month revenue of $8M.
In the same LTM period, Daxor generated $5M in gross profit and had net loss of ($478K).
Revenue (LTM)
Daxor P&L
In the most recent fiscal year, Daxor reported revenue of $10M and net income of $9M.
Daxor expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $8M | XXX | $10M | XXX | XXX | XXX |
| Gross Profit | $5M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (6%) | XXX | (3%) | XXX | XXX | XXX |
| Net Profit | ($478K) | XXX | $9M | XXX | XXX | XXX |
| Net Margin | (6%) | XXX | 89% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Daxor Stock Performance
Daxor has current market cap of $66M, and enterprise value of $67M.
Market Cap Evolution
Daxor's stock price is $11.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $67M | $66M | 0.0% | XXX | XXX | XXX | $1.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDaxor Valuation Multiples
Daxor trades at 8.6x EV/Revenue multiple.
EV / Revenue (LTM)
Daxor Financial Valuation Multiples
As of March 13, 2026, Daxor has market cap of $66M and EV of $67M.
Equity research analysts estimate Daxor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Daxor has a P/E ratio of (138.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV (current) | $67M | XXX | $67M | XXX | XXX | XXX |
| EV/Revenue | 8.6x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBIT | (139.4x) | XXX | (221.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 12.2x | XXX | — | XXX | XXX | XXX |
| P/E | (138.9x) | XXX | 7.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 116.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Daxor Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Daxor Margins & Growth Rates
Daxor's revenue in the last 12 month grew by 77%.
Daxor's revenue per employee in the last FY averaged $0.6M.
Daxor Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 77% | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | — | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 11% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Daxor Public Comps
See public comps and valuation multiples for other Medical Devices and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Accuray | XXX | XXX | XXX | XXX | XXX | XXX |
| Optomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Pangaea Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| InspireMD | XXX | XXX | XXX | XXX | XXX | XXX |
| Optiscan Imaging | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daxor M&A Activity
Daxor acquired XXX companies to date.
Last acquisition by Daxor was on XXXXXXXX, XXXXX. Daxor acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Daxor
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDaxor Investment Activity
Daxor invested in XXX companies to date.
Daxor made its latest investment on XXXXXXXX, XXXXX. Daxor invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Daxor
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Daxor
| When was Daxor founded? | Daxor was founded in 1971. |
| Where is Daxor headquartered? | Daxor is headquartered in United States. |
| How many employees does Daxor have? | As of today, Daxor has over 12 employees. |
| Who is the CEO of Daxor? | Daxor's CEO is Michael R. Feldschuh. |
| Is Daxor publicly listed? | Yes, Daxor is a public company listed on Nasdaq. |
| What is the stock symbol of Daxor? | Daxor trades under DXR ticker. |
| When did Daxor go public? | Daxor went public in 1983. |
| Who are competitors of Daxor? | Daxor main competitors are Accuray, Optomed, Pangaea Oncology, InspireMD. |
| What is the current market cap of Daxor? | Daxor's current market cap is $66M. |
| What is the current revenue of Daxor? | Daxor's last 12 months revenue is $8M. |
| What is the current revenue growth of Daxor? | Daxor revenue growth (NTM/LTM) is 77%. |
| What is the current EV/Revenue multiple of Daxor? | Current revenue multiple of Daxor is 8.6x. |
| Is Daxor profitable? | No, Daxor is not profitable. |
| What is the current net income of Daxor? | Daxor's last 12 months net income is ($478K). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.